| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial ☆
|
Audinot, B.
|
|
|
35 |
6 |
p. 559-568
|
artikel
|
| 2 |
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET ☆
|
Gennari, A.
|
|
|
35 |
6 |
p. 549-558
|
artikel
|
| 3 |
Editorial Board
|
|
|
|
35 |
6 |
p. iii
|
artikel
|
| 4 |
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma
|
Powles, T.
|
|
|
35 |
6 |
p. 485-490
|
artikel
|
| 5 |
Genome-wide association studies and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer
|
Laskar, R.S.
|
|
|
35 |
6 |
p. 523-536
|
artikel
|
| 6 |
Identifying genetic loci associated with an increased risk for early-onset colorectal cancer
|
Kelsen, D.
|
|
|
35 |
6 |
p. 483-484
|
artikel
|
| 7 |
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040 ☆
|
Melero, I.
|
|
|
35 |
6 |
p. 537-548
|
artikel
|
| 8 |
Oncogenic extrachromosomal DNA identification using whole-genome sequencing from formalin-fixed glioblastomas
|
Noorani, I.
|
|
|
35 |
6 |
p. 570-573
|
artikel
|
| 9 |
Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Ferreri, A.J.M.
|
|
|
35 |
6 |
p. 491-507
|
artikel
|
| 10 |
Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?
|
Pourmir, I.
|
|
|
35 |
6 |
p. 569-570
|
artikel
|
| 11 |
Table of Contents
|
|
|
|
35 |
6 |
p. i-ii
|
artikel
|
| 12 |
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities
|
Wang, X.
|
|
|
35 |
6 |
p. 508-522
|
artikel
|
| 13 |
VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
|
Le Cesne, A.
|
|
|
35 |
6 |
p. 576-577
|
artikel
|
| 14 |
VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
|
Li, H.
|
|
|
35 |
6 |
p. 574-575
|
artikel
|
Tijdschrift beschrijving